Background and Aims
Introduction
The 7 th edition of the American Joint Committee on Cancer (AJCC) guidelines [1] [2] for gastric cancer include many controversial changes that have been strongly debated, such as the restaging of gastric cancer and the reclassification of adenocarcinomas of the esophagogastric junction as esophageal carcinomas [3] [4] [5] [6] . However, little attention has been given to the change that the station No.12a lymph nodes (lymph nodes along the proper hepatic artery) are no longer assigned to the D2 lymphadenectomy region and No.12a metastasis is reclassified accordingly as distant metastasis. Both the 6 th edition of AJCC guidelines [7] for gastric cancer and the 3 rd edition of Japanese treatment guidelines for gastric cancer [8] consider No.12a LN metastasis as regional metastasis from a primary gastric cancer that should be dissected during D2 lymphadenectomy to improve patient outcome. Moreover, most surgeons [9] [10] agree that D2 lymphadenectomy is associated with an increased survival benefit in patients with gastric cancer. The differences between the guidelines may cause confusion among surgeons. The aim of this study was to evaluate the clinical importance and survival outcomes of patients with gastric cancer with No.12a LN metastasis and the difference in the efficacy of D2 lymphadenectomy according to the inclusion of metastatic No.12a LNs.
Methods
The study was approved by the Institutional Review Board of the 1st Affiliated Hospital of Sun Yat-Sen University and informed consent was obtained according to institutional regulations. Written informed consent for further clinical research was given by participants for their clinical records to be used when patients were admitted to hospital. Data obtained from patients with gastric cancer who underwent gastrectomy plus D2 or greater lymphadenectomy between January 1996 and December 2006 at the 1st affiliated hospital of Sun Yat-sen University were retrospectively analyzed. Patients who received neoadjuvant chemotherapy or chemoradiotherapy were excluded. The D2 lymphadenectomy region was determined according to the 6th edition AJCC gastric cancer guidelines and included the LNs along the left gastric artery (station No.7), the front of the common hepatic artery (station No.8a), the celiac axis (station No.9), the splenic hilum (station No.10), the splenic artery (station No.11), and the proper hepatic artery (station No.12a).
The clinicopathological features analyzed included age, sex, tumor size, histological tumor type, gross tumor type, tumor location, and cancer embryonic antigen (CEA) level. The histological type was defined as well or poorly differentiated. Poorly differentiated types included poorly differentiated adenoma, mucinous gastric cancer, signet ring cell cancer, and undifferentiated adenoma. The postoperative pathological stage was reclassified according to the 7 th edition of the AJCC gastric cancer guidelines.
Follow-up was conducted every 3-6 months for the first 3 years and once a year thereafter. Patients underwent regular blood tests including a tumor biomarker assessment, endoscopic examination, abdominal computed tomography or ultrasonography, and chest radiography or thoracic computed tomography. The last follow-up date was in December 2013. The mean follow-up time was 41.28 ± 34.84 months.
The chi-square test was used to compare differences in the categorical data. Survival was compared using the log-rank test, and survival curves were generated using the Kaplan-Meier method. The Life-table was used to calculate survival time. Univariate and multivariate analyses were conducted using the Cox proportional hazards regression model and forward logistic regression. Logistic regression analysis was used to determine factors associated with No.12a LN metastasis. A P-value <0.05 was considered statistically significant. All data were analyzed using the Statistical Package for Social Sciences (SPSS 16.0, Chicago, IL, USA). (Table 4 , Fig. 1b) . Moreover, although No.12a LN metastasis influenced the overall survival outcome, it was not an independent predictor (Table 5 ). Table 4 ). In addition, the overall survival rate was significantly different between patients with TNM stage I-III No.12a LN metastasis and those with stage IV No.12a LN metastasis (Fig. 2c , Table 4 ). Finally, the overall survival rate of patients with TNM stage IV No.12a LN metastasis was lower than that of patients with distant metastasis, although the difference was not statistically significant (Fig. 2d , Table 4 ). (Fig. 3a-b , Table 4 ). Moreover, we found that the differences between patients with No.12a LN metastasis and LN metastasis in the D2 dissection region were similar (Fig. 3c, Table 4 ). Similar results were obtained when comparing cases of No.12a LN metastasis excluding those of distant metastasis and cases of LN metastasis in the D2 dissection region (Fig. 3d, Table 4 ). 
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Discussion
Surgery remains the only radical treatment option for patients with gastric cancer [11] . After the optimistic results of a Dutch clinical trial with a 15-year follow-up [12] , D2 lymphadenectomy was widely accepted as the standard surgical procedure for advanced gastric cancer. Currently, there are 2 main staging systems for gastric cancer: the AJCC guidelines and the Japanese treatment guidelines. The AJCC guidelines are used worldwide, but most East Asian countries use both guidelines. Regional differences in gastric cancer are existed between Asian and Western countries with respect to etiology, prevalence, clinicopathological features and No.12a Lymph Node Dissection: Implications for D2 Lymphadenectomy treatment strategy of the disease [13] . Hence some guidelines of the 7th edition UICC/AJCC maybe not suitable for the Asian countries. Both guidelines extol the benefits of D2 lymphadenectomy for the treatment of gastric cancer, but recent editions propound differing opinions in this regard. For example, in the latest edition of the Japanese treatment guidelines, the range of LN dissection is no longer based on the location of gastric cancer, but is decided according to the type of gastrectomy, where both the 6 th and 7 th editions of the AJCC guidelines for gastric cancer base the extent of D2 lymphadenectomy on tumor position. Moreover, in the 7 th edition of the AJCC guidelines for gastric cancer, the exclusion of No.12a LN dissection from D2 lymphadenectomy, was not explained, and may result present challenges when comparing past and present data as well as data between Eastern and Western countries. No.12a Lymph Node Dissection: Implications for D2 Lymphadenectomy Lee et al [14] reported that prognosis differed between patients with hepatoduodenal (No.12) LN metastasis and those with distant metastases. Similarly, in this study, survival outcomes were similar between cases of No.12a LN metastasis and those of LN involvement in the AJCC (7 th edition)-defined D2 lymphadenectomy region, although survival was poorer in No.12a Lymph Node Dissection: Implications for D2 Lymphadenectomy cases of No.12a LN metastasis than in those of distant metastasis. No.12a LN metastasis in the current study was associated with poor malignant tumor behavior and advanced tumor stage. Moreover, No.12a LN metastasis was associated with poor overall survival in patients with gastric cancer. Although the LNs along the bile duct (12b) and portal vein (12p) are excluded from the extent of regular D2 lymphadenectomy, these results support the notion that the No.12a LN metastasis should be considered as regional LN metastasis. Limitations of the current study include its retrospective design. Therefore, this study could not address the likelihood of station No. 12a nodal metastasis in patients deemed candidates for D2 dissection. A prospective randomized controlled study is needed in the future.
In conclusion, the survival outcome of patients with No.12a LN metastasis is similar to that of patients with LN involvement in the D2 lymphadenectomy region and worse than those of patients with distant metastasis, suggesting that the No.12a LN should be included in the definition of the D2 lymphadenectomy region in the gastric cancer guidelines.
